Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Chief Sees Bright Future For Indian Pharma In Trump Era

Executive Summary

Biocon’s chair and managing director, Kiran Mazumdar-Shaw, tells Scrip she sees a strong partnering role for Indian firms in the Trump regime, but adds that “carte blanche” pricing that innovator companies enjoyed could come under check.

You may also be interested in...



Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?

President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.

Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma

Nandini Piramal, executive director of Piramal Enterprises, discusses how things have shaped the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing  “framework” deployed by industry.

Supply Chain Crunch Meets Olympics Shutdown: China, India Drug Makers Brace For Perfect Storm

To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile active ingredient supply chain.

Topics

Related Companies

UsernamePublicRestriction

Register

GB001756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel